New Myriad Genetics Survey Uncovers Women Fear Screenings–But Feel Reassured by the Results
(NASDAQ:MYGN), SALT LAKE CITY, Aug. 13, 2025 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today released findings from its latest Cancer Risk Survey that uncover a striking contradiction in women's attitudes toward health screenings. While 80% of women report being afraid to get screened–primarily due […]